SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (213)8/18/2001 10:55:15 PM
From: tnsaf  Read Replies (1) of 1022
 
Conference on Engineered Antibodies Accelerating Drug Discovery & Development
September 18 - 19, 2001 - Park Hyatt at the Bellevue Hotel - Philadelphia, PA
srinstitute.com
Overview is below

Jason


AGGRESSIVELY FOCUSED ON CUTTING-EDGE SCIENCE IN THE POST GENOMIC RACE FOR PRODUCTS

Organized into 4 Main Sections:
· Post Genomic HTP Antibody R & D
· Novel Targets & Selection
· MAb Generation
· Pre-Clinical/Clinical Progress

New!
· Xenomax Technology: A Highly Efficient System for Generating Fully Human Antibodies
· Burgeoning New Opportunities in the Monoclonal Antibody Marketplace
· Mylotarg(tm), an Anti-CD33 Calichemicin-Antibody Conjugate for the treatment of AML
· Rituxan Treatment of Lymphoma
· Millenium's Rapid Antibody Development Systems

FEATURING:
Abgenix
Amgen
Biosite
Centocor
Eli Lilly & Co.
Epicyte Pharmaceuticals
Genentech
GlaxoSmithKline
ICOS Corporation
IDEC Pharmaceuticals
Imclone Systems
Medarex
Millennium Pharmaceuticals
Wyeth-Ayerst
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News